Literature DB >> 26261604

High expression of COUP-TF II cooperated with negative Smad4 expression predicts poor prognosis in patients with colorectal cancer.

Chaoqun Wang1, Yun Zhou2, Ruoyun Ruan3, Maojin Zheng4, Wencan Han4, Linchuan Liao3.   

Abstract

OBJECTIVE: In order to evaluate whether the role of chicken ovalbumin upstream promoter transcription factor II (COUP-TF II) could sever as a predictor to stratify risk of human colorectal cancer (CRC) patients, and to elucidate the preliminary molecular mechanisms of COUP-TF II involved in the development and advancement of CRC reflected by investigating the relationship of COUP-TF II with PTEN, Smad4.
METHODS: 112 cases tissue microarray and immunohistochemical SP method were used to detect the expression of COUP-TF II, PTEN and Smad4 in CRC tissues and adjacent non-tumorous tissues. The clinical relevance and prognosis of COUP-TF II, PTEN, Smad4 in CRC patients were analyzed. Furthermore, Cox proportional hazards model was performed to indicate the independent prognostic factors for CRC patients using various clinicopathological parameters and COUP-TF II, PTEN and Smad4.
RESULTS: COUP-TF II proteins were positively expressed in 65.2% of CRC tissues and 15.5% paired non-CRC tissues, respectively. The expression of COUP-TF II was significantly correlated with TNM stage and lymph node metastasis and a negative correlation with Smad4 expression. Patients bearing higher levels of COUP-TF II expression showed lower DFS and OS. Most importantly, Cox proportional hazards regression analyses showed COUP-TF II positive/Smad4 negative status (DFS, P=0.001; OS, P=0.005) were independent prognostic factors for CRC patients.
CONCLUSION: Positive COUP-TF II expression levels has significant value in determining CRC stage and metastasis and cooperates with negative Smad4 expression contributing to assess prognosis in patients with colorectal cancer, suggesting Smad4 may be involved in the above regulation progress probably.

Entities:  

Keywords:  COUP-TF II; Colorectal neoplasm; PTEN; prognosis; smad4; tissue microarray

Mesh:

Substances:

Year:  2015        PMID: 26261604      PMCID: PMC4525938     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  22 in total

Review 1.  Risk of lymph node metastasis in submucosal esophageal cancer: a review of surgically resected patients.

Authors:  Ines Gockel; George Sgourakis; Orestis Lyros; Ursula Polotzek; Carl Christoph Schimanski; Hauke Lang; Toshitaka Hoppo; Blair A Jobe
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2011-06       Impact factor: 3.869

2.  Nuclear receptor chicken ovalbumin upstream promoter-transcription factor II (COUP-TFII) modulates mesenchymal cell commitment and differentiation.

Authors:  Xin Xie; Jun Qin; Sue-Hwa Lin; Sophia Y Tsai; Ming-Jer Tsai
Journal:  Proc Natl Acad Sci U S A       Date:  2011-08-22       Impact factor: 11.205

3.  COUP-TFII regulates tumor growth and metastasis by modulating tumor angiogenesis.

Authors:  Jun Qin; Xinpu Chen; Xin Xie; Ming-Jer Tsai; Sophia Y Tsai
Journal:  Proc Natl Acad Sci U S A       Date:  2010-02-03       Impact factor: 11.205

4.  A colorectal cancer classification system that associates cellular phenotype and responses to therapy.

Authors:  Anguraj Sadanandam; Costas A Lyssiotis; Krisztian Homicsko; Eric A Collisson; William J Gibb; Stephan Wullschleger; Liliane C Gonzalez Ostos; William A Lannon; Carsten Grotzinger; Maguy Del Rio; Benoit Lhermitte; Adam B Olshen; Bertram Wiedenmann; Lewis C Cantley; Joe W Gray; Douglas Hanahan
Journal:  Nat Med       Date:  2013-04-14       Impact factor: 53.440

Review 5.  Multiple roles of COUP-TFII in cancer initiation and progression.

Authors:  Lacey M Litchfield; Carolyn M Klinge
Journal:  J Mol Endocrinol       Date:  2012-10-10       Impact factor: 5.098

6.  COUP-TFII inhibits TGF-β-induced growth barrier to promote prostate tumorigenesis.

Authors:  Jun Qin; San-Pin Wu; Chad J Creighton; Fangyan Dai; Xin Xie; Chiang-Min Cheng; Anna Frolov; Gustavo Ayala; Xia Lin; Xin-Hua Feng; Michael M Ittmann; Shaw-Jenq Tsai; Ming-Jer Tsai; Sophia Y Tsai
Journal:  Nature       Date:  2012-11-28       Impact factor: 49.962

7.  Expression and functional pathway analysis of nuclear receptor NR2F2 in ovarian cancer.

Authors:  Shannon M Hawkins; Holli A Loomans; Ying-Wooi Wan; Triparna Ghosh-Choudhury; Donna Coffey; Weimin Xiao; Zhandong Liu; Haleh Sangi-Haghpeykar; Matthew L Anderson
Journal:  J Clin Endocrinol Metab       Date:  2013-05-20       Impact factor: 5.958

8.  Chicken ovalbumin upstream promoter transcription factor II in human breast carcinoma: possible regulator of lymphangiogenesis via vascular endothelial growth factor-C expression.

Authors:  Shuji Nagasaki; Takashi Suzuki; Yasuhiro Miki; Jun-ichi Akahira; Hirotaka Shibata; Takanori Ishida; Noriaki Ohuchi; Hironobu Sasano
Journal:  Cancer Sci       Date:  2009-01-13       Impact factor: 6.716

9.  Identification and characterization of nucleolin as a COUP-TFII coactivator of retinoic acid receptor β transcription in breast cancer cells.

Authors:  Lacey M Litchfield; Krista A Riggs; Alyson M Hockenberry; Laura D Oliver; Katelyn G Barnhart; Jian Cai; William M Pierce; Margarita M Ivanova; Paula J Bates; Savitri N Appana; Susmita Datta; Piotr Kulesza; Jean McBryan; Leonie S Young; Carolyn M Klinge
Journal:  PLoS One       Date:  2012-05-31       Impact factor: 3.240

10.  Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value.

Authors:  Laetitia Marisa; Aurélien de Reyniès; Alex Duval; Janick Selves; Marie Pierre Gaub; Laure Vescovo; Marie-Christine Etienne-Grimaldi; Renaud Schiappa; Dominique Guenot; Mira Ayadi; Sylvain Kirzin; Maurice Chazal; Jean-François Fléjou; Daniel Benchimol; Anne Berger; Arnaud Lagarde; Erwan Pencreach; Françoise Piard; Dominique Elias; Yann Parc; Sylviane Olschwang; Gérard Milano; Pierre Laurent-Puig; Valérie Boige
Journal:  PLoS Med       Date:  2013-05-21       Impact factor: 11.069

View more
  7 in total

Review 1.  Orphan Nuclear Receptors in Colorectal Cancer.

Authors:  Michael E Kelly; Helen M Mohan; Alan W Baird; Elizabeth J Ryan; Des C Winter
Journal:  Pathol Oncol Res       Date:  2018-06-28       Impact factor: 3.201

2.  NR2F2 controls malignant squamous cell carcinoma state by promoting stemness and invasion and repressing differentiation.

Authors:  Federico Mauri; Corentin Schepkens; Gaëlle Lapouge; Benjamin Drogat; Yura Song; Ievgenia Pastushenko; Sandrine Rorive; Jeremy Blondeau; Sophie Golstein; Yacine Bareche; Marie Miglianico; Erwin Nkusi; Milena Rozzi; Virginie Moers; Audrey Brisebarre; Maylis Raphaël; Christine Dubois; Justine Allard; Benoit Durdu; Floriane Ribeiro; Christos Sotiriou; Isabelle Salmon; Jalal Vakili; Cédric Blanpain
Journal:  Nat Cancer       Date:  2021-11-22

3.  Progression inference for somatic mutations in cancer.

Authors:  Leif E Peterson; Tatiana Kovyrshina
Journal:  Heliyon       Date:  2017-04-11

4.  Silencing Smad4 attenuates sensitivity of colorectal cancer cells to cetuximab by promoting epithelial‑mesenchymal transition.

Authors:  Zhenlv Lin; Lin Zhang; Junfeng Zhou; Jiantao Zheng
Journal:  Mol Med Rep       Date:  2019-08-21       Impact factor: 2.952

5.  Clinicopathological Characterization and Prognostic Implication of SMAD4 Expression in Colorectal Carcinoma.

Authors:  Seung-Yeon Yoo; Ji-Ae Lee; Yunjoo Shin; Nam-Yun Cho; Jeong Mo Bae; Gyeong Hoon Kang
Journal:  J Pathol Transl Med       Date:  2019-06-24

6.  Recent progress on the role and molecular mechanism of chicken ovalbumin upstream promoter-transcription factor II in cancer.

Authors:  Seong-Hoon Yun; Joo-In Park
Journal:  J Int Med Res       Date:  2020-04       Impact factor: 1.671

Review 7.  COUP-TFII in Health and Disease.

Authors:  Simone Polvani; Sara Pepe; Stefano Milani; Andrea Galli
Journal:  Cells       Date:  2019-12-31       Impact factor: 6.600

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.